The WFH PACT Program is a 5-year initiative designed to improve outreach and diagnosis and increase access to sustainable care for people with inherited bleeding disorders. This is done through training, education, partnerships, in-country initiatives, and evidence-based advocacy.
The level of care in Zambia has increased significantly over the last few years, thanks to the hard work of many committed stakeholders. The signing of this MoU signifies an exciting new chapter in this journey.
—Cesar Garrido, President, WFH
The MoU was signed as an outcome of the ongoing dialogue between the HFZ, the Zambian MoH and the WFH, with agreement secured during the last visit of the WFH in October 2022 on the ten-year anniversary of the founding of the Haemophilia Foundation of Zambia (HFZ), the Zambian national member organization (NMO). It sets clear objectives for the implementation of the PACT Program over the four years. These objectives include, but are not limited to, increasing the number of people identified with hemophilia and von Willebrand disease (VWD), increasing the proportion of patients on the prophylaxis program, and initiating the procurement of therapeutic products by the government. The HFZ has already begun the initial implementation steps for the Program in close collaboration with the MoH, the key HTCs and the WFH.
“Through this MoU, the government has committed to procure and supply hemophilia treatment products as listed in the essential medicines list,” said Lackson Kasonka, MD, the Permanent Secretary at the Ministry of Health for Zambia. “This is a major step forward and will help us significantly raise the level of care for people with bleeding disorders (PWBDs) in our country.”
To find out more about the WFH Path to Access to Care and Treatment (PACT) Program, please click here.
The PACT (Path to Access to Care and Treatment) Program is supported by funding from Roche, our visionary partner; CSL Behring, Pfizer and Sanofi Genzyme, our leadership partners; and Bayer, Biotest and Grifols, our collaborating partners.